You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDyclonine
Accession NumberDB00645  (APRD00940)
TypeSmall Molecule
GroupsApproved
DescriptionDyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray.
Structure
Thumb
Synonyms
1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone
2-(1-Piperidyl)ethyl P-butoxyphenyl ketone
3-Piperidino-4'-butoxypropiophenone
4-Butoxy-beta-piperidinopropiophenone
4-N-Butoxy-beta-(1-piperidyl)propiophenone
4'-Butoxy-3-piperidinopropiophenone
Diclonina
Dyclocaine
Dyclonin
Dyclonine
Dycloninum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cepacol Sore Throat Sprayspray0.1 %oralReckitt Benckiser (Canada) Inc1999-07-012012-03-23Canada
Sore Throat Relieflozenge3 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.Not applicableNot applicableCanada
Sucrets Black Cherrylozenge3 mg/1oralInsight Pharmaceuticals LLC2009-06-18Not applicableUs
Sucrets Childrens Cherrylozenge1.2 mg/1oralInsight Pharmaceuticals2009-07-28Not applicableUs
Sucrets Extra Strength Mint Flav.loz 3mglozenge3 mgoralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1994-12-311998-08-25Canada
Sucrets for Kidslozenge1.2 mgoralInsight Pharmaceuticals LLC1997-08-15Not applicableCanada
Sucrets for Kidslozenge1.2 mgoralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1992-12-311998-08-25Canada
Sucrets Ms Wintergreenlozenge3 mg/1oralInsight Pharmaceuticals2009-07-28Not applicableUs
Sucrets Regular Strength Lemon Flav.loz 2mglozenge2 mgoralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1994-12-311998-08-25Canada
Sucrets Regular Strength Lemon Flavoured Lozengeslozenge2 mgoralHeritage Brands, A Subsidiary Of Insight Pharmaceuticals Llc1997-08-152009-06-19Canada
Sucrets Sore Throatlozenge3 mgoralInsight Pharmaceuticals LLC2007-05-31Not applicableCanada
Sucrets Sore Throat Spray 0.1% Cherryaerosol.1 %oralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1993-12-311996-09-12Canada
Sucrets Wild Cherrylozenge2 mg/1oralInsight Pharmaceuticals LLC2009-07-28Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
DycloneAstraZeneca
SucretsInsight Pharmaceuticals
Brand mixtures
NameLabellerIngredients
Ambix First AidOrganics Corporation Of America Dba Ambix Laboratories
Benzethonium Chloride and Dyclonine HydrochlorideWalgreen Company
Benzethonium Chloride Plus Dyclonine HydrochlorideCVS Pharmacy
Cepacol Sore ThroatReckitt Benckiser LLC
Skin ShieldInsight Pharmaceuticals
Skin Shield Liquid BandageDel Pharmaceuticals Inc.
Sucrets CompleteInsight Pharmaceuticals LLC
Sucrets Complete Cool CitrusInsight Pharmaceuticals LLC
Sucrets Complete Sore Throat, Cough and IrritationInsight Pharmaceuticals LLC
Sucrets Complete Vapor CherryInsight Pharmaceuticals
Tanac Medicated GelDel Pharmaceutics (Canada) Inc.
Salts
Name/CASStructureProperties
Dyclonine hydrochloride
Thumb
  • InChI Key: KNZADIMHVBBPOA-UHFFFAOYSA-N
  • Monoisotopic Mass: 325.180856852
  • Average Mass: 325.873
DBSALT000651
Categories
UNII078A24Q30O
CAS number586-60-7
WeightAverage: 289.4125
Monoisotopic: 289.204179113
Chemical FormulaC18H27NO2
InChI KeyInChIKey=BZEWSEKUUPWQDQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
IUPAC Name
1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one
SMILES
CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Piperidine
  • Beta-aminoketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.
PharmacodynamicsDyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.
Mechanism of actionLocal anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
Related Articles
AbsorptionReadily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeApproximately 30 to 60 minutes.
ClearanceNot Available
ToxicitySymptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9856
Caco-2 permeable+0.7155
P-glycoprotein substrateSubstrate0.7596
P-glycoprotein inhibitor IInhibitor0.8077
P-glycoprotein inhibitor IINon-inhibitor0.6392
Renal organic cation transporterInhibitor0.7801
CYP450 2C9 substrateNon-substrate0.8107
CYP450 2D6 substrateNon-substrate0.5142
CYP450 3A4 substrateSubstrate0.5313
CYP450 1A2 substrateInhibitor0.8914
CYP450 2C9 inhibitorInhibitor0.793
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8574
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5388
Ames testNon AMES toxic0.7961
CarcinogenicityNon-carcinogens0.8823
BiodegradationNot ready biodegradable0.7106
Rat acute toxicity2.3661 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8071
hERG inhibition (predictor II)Inhibitor0.6351
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astrazeneca lp
Packagers
Dosage forms
FormRouteStrength
Creamtopical
Liquidtopical
Liquidoral
Sprayoral0.1 %
Lozengeoral3 mg/1
Lozengeoral1.2 mg/1
Lozengeoral
Lozengeoral1.2 mg
Lozengeoral2 mg
Lozengeoral3 mg
Aerosoloral.1 %
Lozengeoral2 mg/1
Geltopical
Prices
Unit descriptionCostUnit
Dyclonine hcl powder4.9USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174-175Bockstahler, E.R.; U.S.Patent 2,771,391; November 20,1956; assigned to Allied Laboratories, Inc. Florestano, H.J., Jeffries, S.F., Osborne, C.E. and Bahler, M.E.; U.S. Patent 2,868,689; January 13, 1959; assigned to Allied Laboratories, Inc.
water solubilitySoluble (HCl salt)Not Available
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.046 mg/mLALOGPS
logP4.11ALOGPS
logP3.68ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)15.88ChemAxon
pKa (Strongest Basic)8.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity87.07 m3·mol-1ChemAxon
Polarizability35.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen, “Oral Preparation of Dyclonine Hydrochloride.” U.S. Patent US20080200506, issued August 21, 2008.

US20080200506
General ReferencesNot Available
External Links
ATC CodesN01BX02R02AD04
AHFS Codes
  • 52:16.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.4 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Dyclonine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.
AmisulprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Azaperone.
AzelastineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dyclonine.
BaclofenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
BrimonidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine.
BuprenorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine.
ButacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine.
CitalopramThe risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine.
CocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine.
CyclizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.
DapoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Dyclonine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine.
DextromoramideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
DoxylamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Dyclonine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dyclonine.
DrotebanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Drotebanol.
EcgonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dyclonine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dyclonine.
EntacaponeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine.
EthanolDyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dyclonine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.
EthosuximideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.
EtoperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.
FlurazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dyclonine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.
HalothaneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine.
HydrocodoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
HydroxyzineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine.
LithiumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.
Lu AA21004The risk or severity of adverse effects can be increased when Dyclonine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Dyclonine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.
MesoridazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital.
MetyrosineDyclonine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
MirtazapineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dyclonine.
MolindoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
NabiloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nalbuphine.
NitrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Opium.
OrphenadrineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dyclonine.
OsanetantThe risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.
OxymorphoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paliperidone.
ParaldehydeDyclonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dyclonine.
ParoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine.
PerampanelThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide.
PramipexoleDyclonine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dyclonine.
PrilocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.
PromethazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Dyclonine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine.
RisperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Romifidine.
RopiniroleDyclonine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine.
RotigotineDyclonine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dyclonine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dyclonine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.
SertindoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.
SuvorexantThe risk or severity of adverse effects can be increased when Dyclonine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptDyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine.
TetrabenazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin.
ThalidomideDyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dyclonine.
ThiamylalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine.
ThioridazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.
TrimipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dyclonine.
VigabatrinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.
ZolazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dyclonine.
ZonisamideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Roghani S, Duperon DF, Barcohana N: Evaluating the efficacy of commonly used topical anesthetics. Pediatr Dent. 1999 May-Jun;21(3):197-200. [PubMed:10355012 ]
  4. Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23